Edition:
India

Bellerophon Therapeutics Inc (BLPH.OQ)

BLPH.OQ on NASDAQ Stock Exchange Global Market

2.22USD
16 Feb 2018
Change (% chg)

$0.02 (+0.91%)
Prev Close
$2.20
Open
$2.22
Day's High
$2.22
Day's Low
$2.16
Volume
6,623
Avg. Vol
52,233
52-wk High
$2.71
52-wk Low
$0.95

Latest Key Developments (Source: Significant Developments)

Bellerophon Therapeutics reports Q3 loss per share $0.22
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon provides business update and reports third quarter 2017 financial results.Q3 loss per share $0.22.Says ‍ phase 2a study for inopulse met its primary endpoint​.  Full Article

Bellerophon Therapeutics says selling stockholders may offer, resell up to 38.9 mln shares - SEC filing
Wednesday, 25 Oct 2017 

Oct 24 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon Therapeutics Inc files to say selling stockholders may offer and resell up to 38.9 million shares of co's common stock - SEC filing.Bellerophon Therapeutics Inc - the selling stockholders will receive all of the proceeds from any sales of the shares offered.  Full Article

Bellerophon qtrly loss per share $0.39
Tuesday, 9 Aug 2016 

Bellerophon Therapeutics Inc : Bellerophon reports second quarter 2016 financial results and provides business update . Qtrly loss per share $0.39 . Company believes it has sufficient funds to satisfy its operating cash needs for at least next 12 months . Believes it has sufficient funds to satisfy its operating cash needs for at least next 12 months .Q2 earnings per share view $-0.51 -- Thomson Reuters I/B/E/S.  Full Article

Bellerophon enrolls first patient in phase 3 trial for pulmonary arterial hypertension
Thursday, 16 Jun 2016 

Bellerophon Therapeutics Inc :1 phase 3 clinical trial for pulmonary arterial hypertension (pah).  Full Article

Bellerophon reports Q1 loss per share $0.54
Tuesday, 10 May 2016 

Bellerophon Therapeutics Inc : Bellerophon reports first quarter 2016 financial results and provides business update . Qtrly loss per share $0.54 .Q1 earnings per share view $-0.66 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Bellerophon Says Over 100 Patients In Late-Stage Study Testing Inopulse For Treatment Of High Blood Pressure

* BELLEROPHON THERAPEUTICS ANNOUNCES ENROLLMENT EXCEEDS 100 PATIENTS IN PHASE 3 INOVATION-1 STUDY EVALUATING INOPULSE® FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION